{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T02:24:36Z","timestamp":1758421476403,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jns.2021.117553","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:19:16Z","timestamp":1624522756000},"page":"117553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"427","author":[{"given":"Alex","family":"Exuzides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sheinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shervin","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig S.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jns.2021.117553_bb0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"10.1016\/j.jns.2021.117553_bb0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"10.1016\/j.jns.2021.117553_bb0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000094","article-title":"Sleep abnormality in neuromyelitis optica spectrum disorder","volume":"2","author":"Song","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1\u20132","key":"10.1016\/j.jns.2021.117553_bb0020","first-page":"39","article-title":"MRI characteristics of MOG-ab associated disease in adults: an update","volume":"177","author":"Shor","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.jns.2021.117553_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jns.2021.117553_bb0030","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117553_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117553_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.msard.2019.07.024","article-title":"Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of south Indian patients","volume":"35","author":"Kanikannan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jns.2021.117553_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2019.05.013","article-title":"Neuromyelitis optica testing and treatment: availability and affordability in 60 countries","volume":"33","author":"Holroyd","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.jns.2021.117553_bb0050","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in NMOSD","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jns.2021.117553_bb0055","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2021.117553_bb0060","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.jns.2021.117553_bb0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2021.117553_bb0070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult Scler"},{"issue":"Suppl. 4","key":"10.1016\/j.jns.2021.117553_bb0075","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1007\/s10072-004-0347-8","article-title":"Devic\u2019s neuromyelitis optica and mitochondrial DNA mutation: a case report","volume":"25","author":"Ghezzi","year":"2004","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.jns.2021.117553_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"19","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.jns.2021.117553_bb0085","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.jns.2021.117553_bb0090","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 6","key":"10.1016\/j.jns.2021.117553_bb0095","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2021.117553_bb0100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"10.1016\/j.jns.2021.117553_bb0105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/BOR.0000000000000603","article-title":"Treatment of neuromyelitis optica spectrum disorders","volume":"31","author":"Romeo","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jns.2021.117553_bb0110","unstructured":"FDA News Release: FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system. U.S Food & Drug Administration. Published June 27, 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central. Accessed February 23, 2021."},{"key":"10.1016\/j.jns.2021.117553_bb0115","unstructured":"FDA News Release: FDA approves new therapy for rare disease affecting optic nerve, spinal cord. Second FDA approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option. U.S. Food & Drug Administration. Published June 11, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord. Accessed February 23, 2021."},{"key":"10.1016\/j.jns.2021.117553_bb0120","unstructured":"FDA News Release: FDA approves treatment for rare disease affecting optic nerves, spinal cord. U.S. Food and Drug Administration. Published August 17, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord#:~:text=The%20U.S.%20Food%20and%20Drug,4%20or%20AQP4%20antibody%2Dpositive. Accessed February 23, 2021."},{"issue":"10206","key":"10.1016\/j.jns.2021.117553_bb0125","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jns.2021.117553_bb0130","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"10.1016\/j.jns.2021.117553_bb0140","article-title":"A real-world analysis of relapses and costs of neuromyelitis optica spectrum disorders using a United States administrative claims database (P6.161)","volume":"86","author":"Stafkey-Mailey","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2021.117553_bb0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.jns.2021.117553_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.jns.2021.117553_bb0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:40Z","timestamp":1758383980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21002471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":30,"alternative-id":["S0022510X21002471"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117553","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117553"}}